Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia

References

• Lupo PJ, Spector LG. Cancer progress and priorities: childhood cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(6):1081–1094.
   PubMed Web of Science ®Google Scholar
• Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010;99(6):2557–2575.
   PubMed Web of Science ®Google Scholar
• Withycombe JS, Alonzo TA, Wilkins-Sanchez MA, et al. The children's oncology group: organizational structure, membership, and institutional characteristics. J Pediatr Oncol Nurs. 2019;36(1):24–34.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's cancer group study. Blood. 2002;99(6):1986–1994.
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991–998.
   PubMed Web of Science ®Google Scholar
• Parmentier JH, Maggi M, Tarasco E, et al. Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk Res. 2015;39(7):757–762.
   PubMed Web of Science ®Google Scholar
• Henriksen LT, Harila-Saari A, Ruud E, Nordic Society of Paediatric Haematology and Oncology (NOPHO) Group, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62(3):427–433.
   PubMed Web of Science ®Google Scholar
• Klaassen ILM, Lauw MN, Fiocco M, et al. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis. Res Pract Thromb Haemost. 2019;3(2):234–241.
   PubMed Web of Science ®Google Scholar
• Mateos MK, Trahair TN, Mayoh C, et al. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Thromb Res. 2019;178:132–138.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(2):199–205.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2020;38(17):1897–1905.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175–5181.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, Children’s Oncology Group, et al. Long-term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031. Leukemia 2014;28(7):1467–1471.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Devidas M, Bowman WP, Children’s Oncology Group, et al. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from children's oncology group study AALL0031. Leukemia 2014;28(4):964–967.
   PubMed Web of Science ®Google Scholar
• Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children's oncology group study AALL0232. J Clin Oncol. 2016;34(20):2380–2388.
   PubMed Web of Science ®Google Scholar
• Dunsmore KP, Winter SS, Devidas M, et al. Children's oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38(28):3282–3293.
   PubMed Web of Science ®Google Scholar
• Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children's oncology group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36(29):2926–2934.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Kairalla JA, et al. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from children's oncology group AALL0932. J Clin Oncol. 2021;39(13):1437–1447.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Burke MJ, Devidas M, et al. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: children's oncology group study AALL1131. J Clin Oncol. 2020;38(23):2628–2638.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Devidas M, Wood BL, et al. Children's oncology group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40(19):2106–2118.
   PubMed Web of Science ®Google Scholar
• Nihiser AJ, Lee SM, Wechsler H, et al. Body mass index measurement in schools. J Sch Health. 2007;77(10):651–671.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC growth charts for the United States: methods and development 2010 [cited 2015 July 17]. Available from: http://www.cdc.gov/nchs/data/series/sr_11/sr11_246.pdf.
   Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690.
   PubMed Web of Science ®Google Scholar
• Chaturvedi A, Green PE, Caroll JD. K-modes clustering. J Classif. 2001;18(1):35–55.
   Web of Science ®Google Scholar
• Huang Z, Ng MK. A note on K-modes clustering. J Classif. 2003;20(2):257–261.
   Web of Science ®Google Scholar
• Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(4):748–757.
   PubMed Web of Science ®Google Scholar
• Rank CU, Wolthers BO, Grell K, et al. Asparaginase-Associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age. J Clin Oncol. 2020;38(2):145–154.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fernandez CA, Smith C, et al. Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. Clin Pharmacol Ther. 2017;102(1):131–140.
   PubMed Web of Science ®Google Scholar
• Hashmi SK, Navai SA, Chambers TM, et al. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(2):e28063.
   PubMed Web of Science ®Google Scholar
• Pui CH. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Front Med. 2015;9(1):1–9.
   PubMed Web of Science ®Google Scholar
• Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018;131(22):2475–2484.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood. 2001;97(5):1211–1218.
   PubMed Web of Science ®Google Scholar
• Yi JS, Chambers TM, Getz KD, et al. A report from the leukemia electronic abstraction of records network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 May 1;107(5):1185–1188. PMID: 35081687
   Google Scholar
• Egnell C, Heyman M, Jónsson ÓG, et al. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia. Br J Haematol. 2022;196(5):1239–1247.
   PubMed Web of Science ®Google Scholar
• Orgel E, Sposto R, Malvar J, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2014;32(13):1331–1337.
   PubMed Web of Science ®Google Scholar
• Maggio AB, Mueller P, Wacker J, et al. Increased pancreatic fat fraction is present in obese adolescents with metabolic syndrome. J Pediatr Gastroenterol Nutr. 2012;54(6):720–726.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Moscatiello S, Di Domizio S, et al. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S74–S80.
   PubMed Web of Science ®Google Scholar